Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jnana Therapeutics
Boston, Massachusetts, United Statesjnanatx.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Jnana’s lead asset, JNT‑517, an allosteric inhibitor of SLC6A19 for PKU, has shown effectiveness and safety in a Phase 1b/2 study. The company also has discovery programs targeting IRF3 for autoimmune/inflammatory conditions. Its RAPID chemoproteomics platform enables systematic small molecule drug discovery against previously inaccessible targets like solute carrier transporters and transcription factors.
- Therapeutic areas
- ImmunologyNeurologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Roche – multi-target collaboration/licensing deals focused on SLC transporters for immune-mediated and neurological diseases ($40M upfront + milestones exceeding $1B in first deal; second deal $50M upfront + up to $2B milestones)
Beyond the preview
Go deeper on Jnana Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jnana Therapeutics.